Acticor Biotech News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

15.03.24	Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros (Businesswire)
14.03.24	Acticor Biotech Launches a Capital Increase of a Minimum of 7 Million Euros (Businesswire)
14.09.23	ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatment of Stroke (Businesswire)
07.09.23	The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks (Businesswire)
31.08.23	ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artificial Intelligence Reinforces Glenzocimab Mode of Action in Stroke Patients (Businesswire)
30.05.23	Acticor Biotech: Progress in Discussions with EU and US Regulatory Agencies (Businesswire)
09.03.23	Acticor Biotech Successfully Completes a Capital Increase for a Total Gross Amount of 12.2 Million Euros, via the Issuance of 1,793,005 Shares (Businesswire)
08.03.23	Acticor Biotech Launches a Capital Increase for an Amount of C. 10 Million Euros (Businesswire)
09.01.23	Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies (Businesswire)
05.12.22	Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke (Businesswire)
22.11.22	Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks (Businesswire)
18.10.22	Acticor Biotech Strengthens Its Financial Structure (Businesswire)
26.09.22	Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke (Businesswire)
09.05.22	ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022 (Businesswire)
30.03.22	Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V